Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Authors

Guido Marcucci, City of Hope Comprehensive Cancer Center
Geoffrey L. Uy, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

2020

Volume

4

Issue

4

First Page

696

Last Page

705

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2019000492

Rights and Permissions

Guido Marcucci, Susan Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy, William Blum, Ann-Kathrin Eisfeld, Timothy S. Pardee, Eunice S. Wang, Wendy Stock, Jonathan E. Kolitz, Jessica Kohlschmidt, Krzysztof Mrózek, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson; Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv 2020; 4 (4): 696–705. doi: https://doi.org/10.1182/bloodadvances.2019000492

Recommended Citation

Marcucci, Guido; Uy, Geoffrey L.; and al., et, "Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801." Blood Advances. 4, 4. 696 - 705. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9301